GL1X · GenesisL1 explorer

MolNFT v1 · #117994 · protein

Structure of the murine antibody Fab 8E3 bound to the vaccinia virus A27 peptide 101-110

5EOR · Anti vaccinia virus A27 antibody 8E3 heavy chain: “Structure of the murine antibody Fab 8E3 bound to the vaccinia virus A27 peptide 101-110”. X-ray diffraction, 1 ligand (NA), 5 pockets (best druggability 0.57). MolNFT v1 #117994 on…

PDB
5EOR
Type
protein
Length
440 residues
Chains
3
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Anti vaccinia virus A27 antibody 8E3 heavy chain; Anti vaccinia virus A27 antibody 8E3…
Ligands
NA
Pockets
5 · best druggability 0.57

Structure

x-ray diffraction · 3 distinct chains · 6% helix, 54% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
HAnti vaccinia virus A27 antibody 8E3 heavy chainprotein2144% helix, 54% strand—
LAnti vaccinia virus A27 antibody 8E3 light chainprotein2177% helix, 56% strand—
AProtein A27protein90% helix, 11% strand—

Ligands and binding sites

  • NA · Sodium ion · metal · chains H

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

5 pockets found on a 1 Å grid, 1 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
14510.570.7354empty
21020.380.7523empty
3680.330.7616empty
4510.260.7414empty
5500.250.7314empty

Interfaces

3 interfaces between chains.

  • H–L · 1832 Ų buried · 13 hydrogen bonds · protein-protein
  • L–A · 478 Ų buried · 11 hydrogen bonds · protein-protein
  • H–A · 353 Ų buried · 7 hydrogen bonds · protein-protein

Modifications

Observed in the structure: 4 disulfide (disulfide).

Compared structures

  • 5EOR · Structure of the murine antibody Fab 8E3 bound to the vaccinia virus A27 peptide 101-110 · the same entry in another collection · chain H against H, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.